Guardant Health, Inc. (GH) AI Stock Analysis

Guardant Health, Inc. is a precision oncology company that offers blood tests, data analytics, and precision oncology solutions globally. Its primary offerings include the Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy tests for patients with advanced stage cancer. The company develops diagnostic technologies such as the LUNAR-2 test for early colorectal cancer detection and the Guardant Reveal Test for early-stage cancer therapy selection. Additionally, Guardant Health provides GuardantConnect to link patients to clinical trials, Guardant360 tissue genotyping, Guardant-19 for detecting the novel coronavirus, and companion diagnostic development services for biopharmaceutical companies.

Guardant Health expanded revenue from $373.7M in FY2021 to $982.0M in FY2025, recording annual revenue growth of 32.9% in FY2025. Gross margin shifted from 67.1% in FY2021 to 64.5% in FY2025. Although operating margin improved from -110.0% in FY2021 to -44.5% in FY2025, the company reported annual net losses, including a net income of -$416.3M in FY2025. In the latest quarter ended June 30, 2026, quarterly revenue growth reached 44.3% year-over-year. For the trailing twelve months, revenue reached $1.18B with an operating margin of -38.2% and a profit margin of -38.3%.

As of June 30, 2026, Guardant Health held $1.05B in cash and short-term investments against total debt of $1.70B, resulting in net debt of $643.5M. The company reported a current ratio of 4.03 and negative shareholders' equity of -$222.9M. Cash flows remain negative, with FY2025 operating cash flow of -$184.8M and free cash flow of -$233.1M. During FY2025, the company used $48.3M for capital expenditures and $45.0M for share buybacks.

Guardant Health trades at a price-to-sales multiple of 18.0x and an EV to revenue multiple of 20.6x, compared to a price-to-sales median of 4.1x for its US-listed Healthcare peers. Its price-to-book ratio is 55.7x alongside an enterprise value of $24.42B. Over the past year, the stock generated a return of 135.1%, outperforming the 16.8% return for the S&P 500 (SPY). Over a 5-year period, its return of 56.1% lagged the S&P 500 (SPY) return of 83.0%.

Wall Street analysts hold 20 Strong Buy, 5 Buy, 0 Hold, and 1 Sell ratings on Guardant Health. The mean price target is $201.64, representing a 27.1% premium to the last close of $158.60. For the fiscal year ending December 31, 2026, analysts estimate revenue of $1.36B and an EPS of -$1.46. The company beat EPS estimates in 2 of the last 4 quarters. The next earnings date is November 5, 2026.

This page is an AI-written research summary of Guardant Health, Inc. (GH). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: GH income statement, GH balance sheet, GH key metrics, GH analyst forecast, GH chart. See the GH stock overview for the latest quote and news.